The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.
The user experienced hair thickening and regrowth using dutasteride on alternate days, oral minoxidil every third day, and daily hair massages, but is dealing with dandruff and inflammation. They are considering adjusting their minoxidil dosage and have started using ketoconazole shampoo and cupping therapy for additional benefits.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
A 20-year-old is considering switching from finasteride to dutasteride during a steroid cycle to better manage hair loss, then returning to finasteride afterward. They are concerned about the risks of post-finasteride syndrome from frequently changing medications.
An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.
The user is sharing their experience with using 0.5mg dutasteride, 2.5mg oral minoxidil, and hair dye for 45 days. Another user encourages them to continue as it is still too early to see significant improvement.
The user is considering stopping dutasteride and minoxidil due to side effects like low mood and depression after three weeks of use. They are concerned about hair shedding and are contemplating switching to just minoxidil to see if it helps without affecting mental health.
A user shared their positive 3-month results using a treatment for hair loss that includes Dermaroller, Minoxidil, and Amplexe Shampoo. They avoided using finasteride due to its risks.
User shared before and after photos of 8 months using Finasteride 1mg and Minoxidil 5% 1ml nightly, with positive results and no side effects. Others praised the progress and suggested alternative treatments like topical fin, CB-03-01, or RU58841.
RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.
A 41-year-old man shared his two-year progress using finasteride for hair regrowth, noting significant improvement but wishing he had started earlier. He plans to add oral minoxidil to his routine despite concerns about potential side effects, emphasizing the importance of starting treatment early to combat hair loss.
The post discusses using RU58841 and 5% minoxidil for hair loss treatment, with RU applied to the temples and crown, and minoxidil used twice daily. Users debate the effectiveness of RU58841 compared to minoxidil alone.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.
User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.
The user experienced initial hair regrowth with topical dutasteride and minoxidil but later faced significant hair shedding, leading to doubts about the effectiveness of topical dutasteride. They plan to continue the treatment for a year and may switch to oral finasteride if no improvement is seen.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.
A 31-year-old male experienced significant hair regrowth after 6 months using daily 0.5 mg dutasteride, 5% topical minoxidil twice a day, occasional dermarolling, and hair supplements. He reported a slight decrease in libido initially but no other side effects, and there's potential for further improvement up to 12–18 months.
A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgen receptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).
The user is documenting their experience with oral dutasteride (dut) 0.5 mg and minoxidil (min) 5 mg for hair loss, planning to add RU58841 after three months. They previously used finasteride with success and are now experiencing increased shedding but also new hair growth.
The user has been using 0.5 mg dutasteride and 2.5 mg oral minoxidil for a year, recently adding microneedling and topical minoxidil, with some improvement but the crown remains the weakest area. Consistency and realistic expectations are advised, as progress is slow and coverage is challenging with fine hair.
A user shared their positive experience with hair regrowth after 13 months of using dutasteride and minoxidil, noting improved self-confidence and physical fitness. They reported noticeable results after 2 months, with significant improvement by 7-8 months, and no major side effects.
The user has been on Finasteride for 13 months without results and plans to switch to Dutasteride. They are considering adding Minoxidil to prevent further hair loss and are seeking advice on the effectiveness of combining these treatments.